Yalda Baghay Esfandyari
Overview
Explore the profile of Yalda Baghay Esfandyari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaer S, Aghamaali M, Amini M, Doustvandi M, Hosseini S, Baradaran B, et al.
Bioimpacts
. 2024 Jun;
14(3):29913.
PMID: 38938754
Introduction: As the most common aggressive primary brain tumor, glioblastoma is inevitably a recurrent malignancy whose patients' prognosis is poor. miR-143 and miR-145, as tumor suppressor miRNAs, are downregulated through...
2.
Mozammel N, Baghbani E, Amini M, Zaer S, Baghay Esfandyari Y, Tohidast M, et al.
Adv Pharm Bull
. 2024 Apr;
14(1):231-240.
PMID: 38585468
Purpose: MicroRNAs (miRNAs) are a group of small regulatory non-coding RNAs, which are dysregulated through tumor progression. let-7 and MIR-145 are both tumor suppressor microRNAs that are downregulated in a...
3.
Sameti P, Amini M, Oroojalian F, Baghay Esfandyari Y, Tohidast M, Rahmani S, et al.
Mol Biotechnol
. 2023 Jun;
66(7):1537-1551.
PMID: 37332071
MicroRNAs (miRNAs) are small single-stranded regulatory RNAs that are shown to be dysregulated in a wide array of human cancers. MiRNAs play critical roles in cancer progression and function as...
4.
Baghay Esfandyari Y, Doustvandi M, Amini M, Baradaran B, Zaer S, Mozammel N, et al.
Reprod Sci
. 2021 Feb;
28(7):2036-2049.
PMID: 33569751
Cisplatin-based chemotherapy is commonly used for cervical cancer treatment. However, the development of chemoresistance is considered the main obstacle to the effectiveness of this therapeutic agent. MicroRNAs are illustrated to...